| Drug ID: | Drug196 |
|---|---|
| Drug Name: | Desonide |
| CID: | 5311066 |
| DrugBank ID: | DB01260 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03437005, , NCT02624544, , NCT03386032, , NCT03758365, , NCT00828412, , NCT02732314, , NCT02286700, , NCT01467362, , NCT01542138 |
| Molecular Formula: | C24H32O6 |
| Molecular Weight: | 416.5 g/mol |
| Isomeric SMILES: | C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O |
| Synonyms: | DESONIDE; 638-94-8; Prednacinolone; Desonate; Desonida; Topifug; Desilux; Desonidum; Verdeso; Apolar |
| Phase 0: | 0 |
| Phase 1: | 2 |
| Phase 2: | 0 |
| Phase 3: | 3 |
| Phase 4: | 5 |
| Description: | A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1375 | 5311066 | Desonide | 301 | ANXA1 | Homo sapiens (human) | None | |
| dt1376 | 5311066 | Desonide | 2908 | NR3C1 | Homo sapiens (human) | Glucocorticoid receptor agonist | |
| dt1377 | 5311066 | Desonide | 367 | AR | Homo sapiens (human) | None | |
| dt1378 | 5311066 | Desonide | 2101 | ESRRA | Homo sapiens (human) | Modulator | |
| dt1379 | 5311066 | Desonide | 2103 | ESRRB | Homo sapiens (human) | Modulator | |
| dt1380 | 5311066 | Desonide | 2104 | ESRRG | Homo sapiens (human) | Modulator | |
| dt1381 | 5311066 | Desonide | 2908 | NR3C1 | Homo sapiens (human) | None | |
| dt1382 | 5311066 | Desonide | 2101 | ESRRA | Homo sapiens (human) | 37713619 | Modulator |
| dt1383 | 5311066 | Desonide | 2103 | ESRRB | Homo sapiens (human) | 37713619 | Modulator |
| dt1384 | 5311066 | Desonide | 2104 | ESRRG | Homo sapiens (human) | 37713619 | Modulator |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT01100112 | (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Colitis, Ulcerative | DRUG: Budesonide | Details |
| NCT01532648 | Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Budesonide MMX|DRUG: Placebo|DRUG: 5-ASA | Details |
| NCT02586259 | Effectiveness of Cortiment in Patients With Ulcerative Colitis | None | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | DRUG: budesonide MMX | Details |
| NCT00747110 | Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC) | PHASE3 | COMPLETED | Dr. Falk Pharma GmbH | Colitis, Ulcerative | DRUG: budesonide|DRUG: mesalazine | Details |
| NCT05976802 | Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis | PHASE4 | NOT_YET_RECRUITING | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: High dose budesonide rectal foam|DRUG: Low … | Details |
| NCT04314375 | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis | PHASE4 | RECRUITING | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Low Dose Budesonide|DRUG: High Dose Budeson… | Details |
| NCT00801723 | (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Budesonide MMX 6 mg Tablet|DRUG: Placebo Ta… | Details |
| NCT02550418 | Budesonide 9 mg Capsules in Active UC | PHASE2 | COMPLETED | Dr. Falk Pharma GmbH | Colitis, Ulcerative | DRUG: Budesonide | Details |
| NCT01349673 | The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | TERMINATED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide Foam | Details |
| NCT01008423 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide|DRUG: Placebo | Details |
| NCT01008410 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide|DRUG: Placebo | Details |
| NL-OMON25521 | Microbiota targeted therapy as alternative for prednisolone and biologicals in IBD patients during the current COVID-19 threat: a prospective study addressing the safety of Budesonide in combination with rifaximin or the Crohns Disease Exclusion Diet (CDED) | Not Available | No | Nestlé 23/08/2021 | None | The results of this prospective study may result … | Details |
| NL-OMON49003 | A randomised controlled trial comparing FMT (fecal microbiota transplantation) after budesonide or placebo in patients with active ulcerative colitis: ;Acronym: the FECBUD trial __ - FMT for ulcerative colitis after initiation of budesonide | Not Available | Not Recruiting | Leids Universitair Medisch Centrum | inflammatory bowel disease ulcerative colitis;10… | Intervention Patients with active ulcerative coli… | Details |
| JPRN-UMIN000031016 | Efficacy and safety of local budesonide for pouchitis - Efficacy of budesonide for pouchitis | PHASE1 | Not Recruiting | Hyogo College of Medicine Department of Inflammatory Bowel Disease | ulcerative colitis pouchitis | None | Details |
| NL-OMON44482 | A randomised controlled trial comparing FECal Microbiota Transplantation after BUDesonide or placebo induction in patients with ulcerative colitis; the FECBUD trial__ - FMT for ulcerative colitis after initiation of budesonide | Not Available | None | Haaglanden Medisch Centrum | inflammatory bowel disease ulcerative colitis;10… | Intervention Patients with active ulcerative coli… | Details |
| NCT05791487 | Combination of Diet and Oral Budesonide for Ulcerative Colitis | None | RECRUITING | Wolfson Medical Center | Ulcerative Colitis|Ulcerative Colitis Chronic Mil… | OTHER: Ulcerative colitis Exclusion Diet|OTHER: P… | Details |
| NCT05341401 | Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis | PHASE2|PHASE3 | UNKNOWN | Assiut University | Ulcerative Colitis Chronic | DRUG: Budesonide MMX|DRUG: Prednisolone | Details |
| NCT00805285 | The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis | PHASE2 | TERMINATED | University of Maryland, Baltimore | Inflammatory Bowel Disease|Ulcerative Colitis | DRUG: Combination Oral Budesonide and Rectal Hydr… | Details |
| NCT03412682 | To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis | PHASE3 | COMPLETED | Ferring Pharmaceuticals | Colitis, Ulcerative | DRUG: Budesonide (6 mg)|DRUG: Budesonide (9 mg)|D… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Preparation and characterization of pH-sensitive nanoparticles of budesonide fo…
PMID: 30174414
Year: 2018
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: The aim of this study was to develop pH sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. METHODS: The NPs sy…
Reviewing the therapeutic role of budesonide in Crohn's disease
PMID: 30007787
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Oral budesonide is a glucocorticoid of primarily local action. In the field of digestive diseases, it is used mainly in inflammatory bowel disease, b…
Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease …
PMID: 29922676
Year: 2018
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: US and European guidelines recommend budesonide for the treatment of mild-to-moderate active ileocolic Crohn's disease (CD). However, bud…
Budesonide with multi-matrix technology as second-line treatment for ulcerative…
PMID: 29857775
Year: 2018
Relationship Type:
Treatment
Score: 6.3
AIMS: Budesonide with multi-matrix technology (MMX) is an oral corticosteroid, shown to have high topical activity against ulcerative colitis (UC) wh…
Oral budesonide in gastrointestinal and liver disease: A practical guide for th…
PMID: 29603368
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Oral budesonide is a second-generation steroid that allows local, selective treatment of the gastrointestinal tract and the liver, minimizing systemi…
Process, optimization, and characterization of budesonide-loaded nanostructured…
PMID: 29376433
Year: 2018
Relationship Type:
Treatment
Score: 6.3
The major challenge involved in the treatment of inflammatory bowel disease is targeted delivery of the drug at the site of inflammation. As nanopart…
Budesonide (Cortiment MMX)
PMID: 29356466
Year: 2017
Relationship Type:
Mechanism
Score: 6.3
Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) that is localized to the colon, and symptoms include diarrhea, pain, bloody sto…
Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disea…
PMID: 28612627
Year: 2017
Relationship Type:
Treatment
Score: 6.3
Crohn's disease (CD) is a chronic inflammatory disorder that commonly affects the terminal ileum and proximal colon. Although systemic corticosteroid…
Enteric-coated budesonide for the induction and maintenance of remission of Cro…
PMID: 28420280
Year: 2017
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-mod…
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Modera…
PMID: 28333362
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND AND AIMS: Safety and efficacy of budesonide multimatrix, an oral extended-release second-generation corticosteroid designed for targeted d…
Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Bu…
PMID: 28146003
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Induction treatment of mild-to-moderate Crohn's disease is controversial. PURPOSE: To compare the induction of remission between differen…
Budesonide foam for mild to moderate distal ulcerative colitis: A systematic re…
PMID: 27699863
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND AND AIM: Budesonide is a second-generation steroid with prominent topical effects and minimal systemic activity for patients with ulcerati…
The glucocorticoid budesonide has protective and deleterious effects in experim…
PMID: 27431777
Year: 2016
Relationship Type:
Mechanism
Score: 6.3
Glucocorticoids are widely used for the management of inflammatory bowel disease, albeit with known limitations for long-term use and relevant advers…
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients …
PMID: 27416045
Year: 2016
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Rectal budesonide foam is a second-generation corticosteroid efficacious for active mild to moderate ulcerative proctitis and ulcerative …
Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoi…
PMID: 27274301
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis (UC) is an immune-mediated disease of the colon that is characterized by diffuse and continuous inflammation contiguous from the r…
Budesonide for the treatment of ulcerative colitis
PMID: 27157244
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Budesonide is a synthetic corticosteroid characterized by enhanced topical potency and limited systemic bioavailability. Its use in ulcerative coliti…
Development of a zero-order sustained-release tablet containing mesalazine and …
PMID: 27000751
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis (UC) and Crohn's disease (CD) are diseases affecting the gastrointestinal tract. Treatment depends on the severity of the disease,…
Budesonide-hydroxypropyl-β-cyclodextrin inclusion complex in binary poloxamer 4…
PMID: 26674842
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Budesonide (BUD) is a glucocorticoid widely used for the treatment of ulcerative colitis. In this work, we propose the study of the system BUD-HP-bet…
Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
PMID: 26541989
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder in which patients cycle between active disease and remission. Budesonide multi-…
Oral budesonide for induction of remission in ulcerative colitis
PMID: 26497719
Year: 2015
Relationship Type:
Treatment
Score: 6.3
Update of Cochrane Database Syst Rev. 2009;(1):CD002913. BACKGROUND: Corticosteroids are effective for induction, but not maintenance of remiss…